Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 14/20 | 0.59 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.59 |
| ▸ | BRD7 | Q9NPI1 | 3/20 | 0.59 |
| ▸ | BRD2 | P25440 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13979671 | 0.82 | BRD4 (0.56) | BRD4BRD9BRD7L3MBTL1 | |
| SCHEMBL9919108 | 0.81 | BRD9 (0.48) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL2611508 | 0.80 | BRD4 (0.59) | BRD4BRD9BRD7L3MBTL1 | |
| SCHEMBL10261961 | 0.79 | GPR84 (0.67) | HTR6HTR2AHTR2CHTR2B | |
| SCHEMBL9922247 | 0.77 | BRD4 (0.46) | BRD4BRD9BRD7BRD2HTR2A | |
| SCHEMBL19869887 | 0.76 | BRD4 (0.64) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL14518831 | 0.76 | BRD4 (0.50) | BRD4BRD9BRD7L3MBTL1 | |
| Iodomethane SCHEMBL4607667 | 0.76 | GPR84 (0.62) | HTR6HTR2AHTR2CHTR2B | |
| SCHEMBL19869876 | 0.75 | BRD4 (1.00) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL26142005 | 0.75 | BRD4 (0.55) | BRD4BRD9BRD7BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1566380-B1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | PARP1, NQO1, PARP3 | BRD4 549/4885BRD9 2267/4885BRD7 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.